Fig. 3From: Effectiveness and safety of omalizumab in patients with allergic bronchopulmonary aspergillosis with or without allergic rhinitis: a retrospective chart reviewAcute exacerbation rate (a) and hospitalization rate (b). Acute exacerbation rate (a) and hospitalization rate (b) in patients with and without allergic rhinitis (AR) before and after omalizumab administration. *p < 0.05. **p < 0.01. ***p > 0.05Back to article page